Arcus Biosciences, Inc. (RCUS)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 601
- Market Cap
- $3.6B
About Arcus Biosciences, Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
SentiSense also tracks daily options readings for Arcus Biosciences, Inc.: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Arcus Biosciences, Inc. stock analysis, sentiment tracking, and market intelligence on SentiSense.